{"product_id":"drts-pestle-analysis","title":"(DRTS) Alpha Tau Medical Ltd. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Alpha Tau Medical Ltd. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces affecting the company and why they matter for strategy and investment. The page shows a real preview of the report so you can assess style and depth; purchase the full version to get the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2-country development footprint: Israel and the United States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.’s work in Israel and the United States means it must align with two health-policy systems, including U.S. FDA rules and Israel Ministry of Health oversight. That can speed site access and patient recruitment, but it also raises coordination costs across protocol, ethics, and reporting steps. Cross-border trials help spread risk, yet they also increase exposure to changing public-sector priorities in both markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeadquarters in Jerusalem, Israel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd., founded in 2015 and based in Jerusalem, benefits from Israel’s strong biotech and healthcare policy support, including a national R\u0026amp;D spend above 6% of GDP in recent years. Jerusalem gives access to talent, universities, and clinical know-how that can help early-stage medical tech move faster. But the same location also exposes Company Name to Israel’s domestic political risk and security volatility, which can disrupt operations, trials, and investor sentiment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage oncology assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. remains clinical-stage, so regulator and public-hospital choices still drive trial speed, site access, and cost. Oncology studies are tightly watched by national health authorities because cancer is a major burden: WHO reported about 20 million new cases and 9.7 million deaths in 2022. Political backing for cancer innovation can shorten approvals and open more trial centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital and government collaboration reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.’s hospital-led therapy model depends on partner sites, ethics committees, and public research systems, so policy shifts in hospital funding or trial rules can hit execution fast. In 2025, that matters because every delayed approval can push back patient enrollment and data readout, which slows the path to key clinical milestones.\u003c\/p\u003e\n\u003cp\u003eDelays also raise operating risk for a development-stage company that must keep studies moving through hospital governance and public review. If a site takes weeks or months longer to clear, trial timelines slip and costs can rise before new data are ready.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospital access is a critical gate.\u003c\/li\u003e\n\u003cli\u003ePublic approvals can delay enrollment.\u003c\/li\u003e\n\u003cli\u003ePolicy changes can slow trials.\u003c\/li\u003e\n\u003cli\u003eData readouts can slip with approvals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeopolitical exposure in Israel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.’s Israel-based operations face persistent geopolitical risk, and the Israel-Hamas war has already driven 300,000+ reserve call-ups, which can disrupt staffing, travel, logistics, and clinic continuity. For a company running clinical activity, even short interruptions can slow patient enrollment and site coordination. Investors also tend to price in higher execution risk when operations sit in a conflict zone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStaffing can tighten fast.\u003c\/li\u003e\n\u003cli\u003eLogistics and travel can be delayed.\u003c\/li\u003e\n\u003cli\u003eOperational risk can weigh on valuation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual Oversight and Conflict Risk Could Slow Trial Timelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompany Name faces political risk from dual oversight in Israel and the United States, so FDA and Health Ministry rules can slow trials and site setup. Its Jerusalem base also brings state biotech support, but conflict risk can disrupt staffing, travel, and clinic flow. In cancer care, public hospital and ethics approvals still shape enrollment speed.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeopolitics\u003c\/td\u003e\n\u003ctd\u003e300,000+ reserve call-ups\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth policy\u003c\/td\u003e\n\u003ctd\u003eFDA and Israel MOH oversight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology demand\u003c\/td\u003e\n\u003ctd\u003e20M new cases, 9.7M deaths in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps the key Political, Economic, Social, Technological, Environmental, and Legal forces shaping Alpha Tau Medical Ltd.’s strategy and risk outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Alpha Tau Medical PESTLE snapshot that speeds risk review and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources to back market sizing, pricing, and competitive assumptions for Alpha Tau Medical, speeding due diligence and traceability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage business model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. is still a clinical-stage company, so most spending goes to R\u0026amp;D, trials, and manufacturing scale-up, not steady product sales. That makes cash burn and future financing needs the key economic issues, since revenue is still limited while operating costs stay high. In practice, valuation depends more on trial progress, regulatory milestones, and access to capital than on near-term earnings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology market with high unmet need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. targets solid tumors with major unmet need, especially pancreatic cancer, which caused about 511,000 new cases and 467,000 deaths worldwide in 2022, and brain\/CNS tumors, which added roughly 321,000 new cases. If efficacy is proven, this severity can support premium pricing. The upside still hinges on clinical results and reimbursement access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-site trial cost structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. runs studies in Israel and the United States, so each added site lifts monitoring, data, and compliance spend. Multi-country trials also mean more ethics reviews and protocol amendments, which push R\u0026amp;D higher.\u003c\/p\u003e\n\u003cp\u003eThat cost load can slow broader indication testing and delay readouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCurrency exposure: shekel and US dollar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd faces clear shekel\/US dollar FX risk because Israel-based operations likely fund local payroll and overhead in shekels, while US development and any future sales may be dollar-linked. In 2025, the shekel traded roughly around 3.6 to 3.9 per US dollar, so even modest swings can change reported R\u0026amp;D spend, grant values, and budget plans.\u003c\/p\u003e\n\u003cp\u003eThis matters because a stronger shekel raises dollar-based costs in Israel, while a weaker shekel can lift translated revenue and cash balances. For a clinical-stage Company Name, timing also matters: costs hit now, but future revenues may arrive in a different currency mix, so FX can distort margins before any product scale-up.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIsrael costs: shekel-heavy\u003c\/li\u003e\n\u003cli\u003eUS development: dollar-heavy\u003c\/li\u003e\n\u003cli\u003e2025 USD\/ILS: about 3.6-3.9\u003c\/li\u003e\n\u003cli\u003eFX swings affect results and budgets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital market dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. relies on equity and other external funding to keep trials moving, so capital access is a core economic risk. In a high-rate setting, with U.S. policy rates at 4.25%-4.50% in 2025, investor demand for high-risk oncology names can tighten fast, which can slow enrollment, site starts, and data readouts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFunding gaps can delay trial execution.\u003c\/li\u003e\n\u003cli\u003eMarket sentiment can shift faster than science.\u003c\/li\u003e\n\u003cli\u003eLower rates usually help biotech financing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlpha Tau Medical: Cash Burn, FX, and Tight Capital Drive 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. remains a cash-burning clinical-stage Company Name, so 2025 economics are driven by R\u0026amp;D spend, trial scale-up, and financing access rather than sales. FX risk also matters: the shekel traded about 3.6-3.9 per US dollar in 2025, which can swing Israel-based costs. With US policy rates at 4.25%-4.50% in 2025, equity funding can stay tight.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash burn\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D-led\u003c\/td\u003e\n\u003ctd\u003eHigh funding need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX\u003c\/td\u003e\n\u003ctd\u003eUSD\/ILS 3.6-3.9\u003c\/td\u003e\n\u003ctd\u003eBudget swings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRates\u003c\/td\u003e\n\u003ctd\u003e4.25%-4.50%\u003c\/td\u003e\n\u003ctd\u003eTighter capital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAlpha Tau Medical Ltd. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Alpha Tau Medical Ltd. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh global cancer burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCancer remains a huge social burden: IARC estimated 20.0 million new cases and 9.7 million deaths worldwide in 2022, with cases projected to hit 35 million by 2050. That keeps demand high for better solid-tumor therapies across many patient groups. For Alpha Tau Medical Ltd., this social pressure supports adoption of treatments for hard-to-treat cancers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e5 key solid tumor areas in active development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.'s work spans skin, oral, pancreatic, and breast cancers, with preclinical programs in liver, brain, and lung disease, covering cancers that affect millions; GLOBOCAN 2022 estimated 20.0 million new cases and 9.7 million deaths worldwide. \u003c\/p\u003e\n\u003cp\u003eBecause these cancers often have poor outcomes or few options, patient groups and clinicians may be more open to new local treatments. \u003c\/p\u003e\n\u003cp\u003eThat broad disease reach can also support trial recruitment and treatment adoption. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeed for less invasive cancer care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients usually favor cancer care that cuts pain, speeds recovery, and reduces repeat visits. In the U.S., about 2.0 million new cancer cases were projected in 2024, so even small gains in comfort matter. Alpha Tau Medical Ltd.'s localized radiation may appeal if it better protects healthy tissue than standard broader therapy, but uptake will hinge on clear proof versus current care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAging population and rising oncology demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder adults carry most cancer burden: WHO estimates 20 million new cases and 9.7 million deaths in 2022, with risk rising sharply after age 65. By 2050, people aged 65+ will reach about 1.6 billion, which supports durable demand for Alpha Tau Medical Ltd. oncology innovation, especially treatments that can suit frailer patients with fewer side effects.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore aging means more cancer.\u003c\/li\u003e\n\u003cli\u003eDemand stays strong long term.\u003c\/li\u003e\n\u003cli\u003eGentler care matters more.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhysician adoption of novel radiation methods\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhysician adoption of Alpha Tau Medical Ltd.'s Alpha DaRT depends on trust in the evidence: clinicians want clear safety, response, and durability data from trials plus real-world cases before changing practice. In oncology, new devices usually face a slow uptake until peers see repeatable results.\u003c\/p\u003e\n\u003cp\u003eTraining and workflow fit matter too, because a radiation platform that adds steps or needs special handling can be hard to scale across hospitals. If use is simple and integrates with existing radiation teams, adoption should move faster.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial proof drives clinician trust\u003c\/li\u003e\n\u003cli\u003eReal-world use speeds peer acceptance\u003c\/li\u003e\n\u003cli\u003eEasy training improves hospital uptake\u003c\/li\u003e\n\u003cli\u003eWorkflow fit can decide rollout speed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging Populations Fuel Demand for Gentler Cancer Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSociology favors Alpha Tau Medical Ltd. because cancer burden is rising and older adults carry most cases: WHO reported 20.0 million new cases and 9.7 million deaths in 2022, with people 65+ set to reach about 1.6 billion by 2050. Patients and doctors also prefer gentler care, so proof of less pain, fewer visits, and better tissue sparing can drive uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eAging\u003c\/td\u003e\n\u003ctd\u003e65+ to 1.6B by 2050\u003c\/td\u003e\n\u003ctd\u003eMore cancer demand\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlpha DaRT platform technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha DaRT (Diffusing Alpha-emitters Radiation Therapy) uses implanted radium-224 sources to emit alpha particles locally inside solid tumors. Alpha particles travel less than 100 microns, so the dose stays highly focused and can spare nearby tissue. This is Alpha Tau Medical Ltd.'s main tech edge, and it underpins its clinical and commercial case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlpha-particle treatment mechanism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha particles can deposit about 50 to 230 keV\/μm and travel only roughly 50 to 100 μm in tissue, so Alpha Tau Medical Ltd’s approach can kill tumor cells while sparing nearby healthy tissue. The mechanism depends on exact placement and controlled delivery, because even a small miss can cut the dose to the target. In 2025, the company said its Alpha DaRT program was being advanced in multiple solid-tumor studies, where that precision is the key technical edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical testing across multiple tumor types\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. is testing its platform in 4 active tumor types: skin, oral, pancreatic, and breast cancer, while preclinical work also covers hepatic cell carcinoma, glioblastoma multiforme, and lung cancer. This 7-indication spread widens the technical proof base and can support label expansion. But it also adds trial design, site, and endpoint complexity across very different tumors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRadiation delivery and dosimetry control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.'s radiation delivery depends on millimeter-level source placement, dose, and treatment time, so even tiny errors can change safety and tumor kill. That makes imaging, planning, and QA non-negotiable. One weak control step can offset the whole treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMillimeter accuracy matters.\u003c\/li\u003e\n\u003cli\u003eSmall dose drift can hurt efficacy.\u003c\/li\u003e\n\u003cli\u003eQC and imaging must be tight.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a platform built around precise local radiation, process control is a core technology risk and a key differentiator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing and handling of radioactive materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.’s alpha-emitter platform depends on tight control of radioactive source manufacture, storage, and cold-chain transport; radium-224, the core isotope in Alpha DaRT, has a 3.66-day half-life, so timing and shielding matter. Batch consistency is critical because small handling errors can change dose delivery and clinical reproducibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShort half-life raises logistics risk.\u003c\/li\u003e\n\u003cli\u003eGMP scale-up is hard and costly.\u003c\/li\u003e\n\u003cli\u003eUniform source loading protects efficacy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlpha Tau’s Precision Edge: Tiny Range, Big Tumor Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.'s edge is precise, local alpha radiation: radium-224 has a 3.66-day half-life, and alpha particles travel only 50 to 100 μm. That makes imaging, millimeter placement, and source control critical, but it also supports focused tumor kill with limited nearby tissue damage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadium-224 half-life\u003c\/td\u003e\n\u003ctd\u003e3.66 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlpha range\u003c\/td\u003e\n\u003ctd\u003e50 to 100 μm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose density\u003c\/td\u003e\n\u003ctd\u003e50 to 230 keV\/μm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial approvals in Israel and the United States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. must clear ethics and regulator review in two systems, Israel and the United States, before moving clinical work forward. In the United States, FDA IND rules govern trial start, while protocol changes and serious safety events must be reported under strict timelines; in Israel, hospital ethics committees and the Ministry of Health also control permission. Any delay in either market can push enrollment and extend timelines by months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiation safety and nuclear material rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha-emitting therapies face tight radiation-handling rules, so Alpha Tau Medical Ltd. must keep facility controls, transport logs, and waste disposal aligned with local nuclear safety law. In the U.S., nuclear material use is governed under NRC 10 CFR Part 20, and any breach can delay trials, block shipments, or trigger fines. That makes compliance a direct operating risk, not just a legal detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property protection for Alpha DaRT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha DaRT depends on strong patent coverage because a novel oncology platform can be copied if core dose-delivery or device claims are weak. Patent terms usually run 20 years from filing, so filing speed and claim scope matter for long exclusivity. Strong IP can support pricing power and investor confidence, while gaps can invite faster biosimilar-like competition and lower margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient data privacy and clinical records\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical development collects sensitive health data, so Alpha Tau Medical Ltd. must handle records under each jurisdiction’s privacy rules, including GDPR health-data limits and HIPAA controls where relevant. A breach can trigger legal exposure of up to 20 million euros or 4 percent of global turnover under GDPR, plus patient and investigator trust loss. That makes consent, access control, and retention rules a direct legal risk, not just an IT issue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHealth data needs strict local-law compliance\u003c\/li\u003e\n\u003cli\u003eBreaches can mean large fines and claims\u003c\/li\u003e\n\u003cli\u003eTrust loss can slow trial recruitment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct liability and treatment claims\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncology therapies face high legal exposure because outcomes can vary by tumor type, stage, and prior treatment. Safety claims, adverse events, and informed consent are central, and U.S. product-liability awards can be large in treatment cases; the FDA logged 1.2 million serious adverse event reports in 2025 across all products. As Alpha Tau Medical Ltd. moves toward commercial use, trial-to-market claim risk rises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh variance in patient outcomes\u003c\/li\u003e\n\u003cli\u003eSafety and consent are key liabilities\u003c\/li\u003e\n\u003cli\u003eCommercial launch raises exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlpha Tau Medical’s Legal Risks: Privacy, Radiation, and Patent Defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. faces legal risk from regulator approvals, radiation rules, patent defense, and health-data laws across Israel, the United States, and the EU. GDPR fines can reach \"20 million euros or 4% of global turnover\", while U.S. NRC controls 10 CFR Part 20 for alpha-emitting materials. Strong IP and clean consent records are key to keeping trials on track and protecting value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivacy\u003c\/td\u003e\n\u003ctd\u003eGDPR fine cap \"20 million euros or 4%\"\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiation\u003c\/td\u003e\n\u003ctd\u003eU.S. NRC 10 CFR Part 20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003ePatent term 20 years from filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadioactive waste handling requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd’s alpha-emitter therapies use Ra-224, which has a 3.66-day half-life, so radioactive waste is time-sensitive and must be tracked from clinic to disposal. Handling rules at clinical and manufacturing sites need strict segregation, storage, and transport controls. Environmental compliance is tied to radiation safety, because any breach can trigger waste, license, and decontamination costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized transport and containment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd. must ship radioactive components in sealed, shielded packs because lead-212 has a 10.6-hour half-life, so delays quickly cut usable activity. Any leak or late delivery can raise contamination and worker-safety risk, especially when materials cross hospitals and labs. That makes fast, trackable logistics and validated containment essential to keep exposure low and product loss down.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy and resource use in R\u0026amp;D facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.’s R\u0026amp;D labs likely face a heavy energy load: biotech labs can use 3-10x more energy per square foot than office space because of fume hoods, HVAC, and cold storage. Single-use plastics also add waste and disposal cost. Better energy control and reuse can cut emissions and lower operating spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealth, safety, and environmental compliance in labs and clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.’s lab and clinic work depends on strict EHS controls for air handling, radiation shielding, hazardous storage, and emergency response. These controls lower exposure risk for staff and patients, and also protect nearby facilities from contamination or accidental release. In healthcare, safety failures can halt trials fast, so compliance is a core operating issue, not just a legal one.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAir flow and filtration matter\u003c\/li\u003e\n\u003cli\u003eShielding limits exposure risk\u003c\/li\u003e\n\u003cli\u003eSafe storage cuts incident odds\u003c\/li\u003e\n\u003cli\u003eResponse plans protect clinics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply chain sensitivity to environmental disruption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.'s clinical and manufacturing supply chains are exposed to transport delays, extreme weather, and power or port outages. The need to move specialized oncology devices, sterile materials, and trial equipment on time makes continuity planning critical, especially when even short delays can slow patient enrollment or site activation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eBuild backup routes and carriers.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHold safety stock for key inputs.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTest trial-continuity plans often.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTrack weather and infrastructure risks.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eResilience matters because global logistics shocks can stretch lead times by weeks, so Alpha Tau Medical Ltd. needs redundancy across suppliers, labs, and shipment lanes to protect trial schedules and manufacturing output.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlpha Tau’s Radioactive Waste and Logistics Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlpha Tau Medical Ltd.’s environmental risk is driven by radioactive materials: Ra-224 has a 3.66-day half-life and lead-212 10.6 hours, so waste, shielding, and delivery delays all raise contamination and disposal risk. Lab energy use can be 3-10x office space, so HVAC and cold-chain power also matter. Climate and logistics shocks can still slow trials and site activation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRa-224 decay\u003c\/td\u003e\n\u003ctd\u003e3.66 days\u003c\/td\u003e\n\u003ctd\u003eTime-sensitive waste\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-212 decay\u003c\/td\u003e\n\u003ctd\u003e10.6 hours\u003c\/td\u003e\n\u003ctd\u003eFast transport needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab power use\u003c\/td\u003e\n\u003ctd\u003e3-10x office\u003c\/td\u003e\n\u003ctd\u003eHigher energy cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234318459145,"sku":"drts-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/drts-pestle-analysis.webp?v=1785717094","url":"https:\/\/dcfanalyst.com\/products\/drts-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}